Tuesday, May 29, 2018 - 11:10am - 12:00pm
Jana Gevertz (The College of New Jersey)
The heterogeneous nature of cancer observed across different regions of the primary tumor, across metastatic sites, across time, and across patients makes designing efficacious yet tolerable therapies a challenge. Both standard of care and personalized treatment protocols run the risk of not exhibiting a robust anti-tumor response in the face of these uncertainties. Here we introduce a platform for exploring this robustness question.
Saturday, September 16, 2017 - 11:20am - 11:50am
Yi-Hsiang Hsu (Harvard Medical School)
The fast moving of the cancer immunotherapy field has generated tremendous excitement regarding new therapeutic strategies and will likely change the paradigm of therapeutic interventions for cancer. Neoantigens, generated by tumor-specific DNA alterations that result in the formation of novel protein sequences and only in cancer cells, represent an optimal target for the immune system and make possible a new class of highly personalized vaccines with the potential for significant efficacy with reduced side effects.
Subscribe to RSS - immunotherapy